JAK Inhibitors

JAK1

JAK2

JAK3

Tyk2

JAK

JAK Inhibitors, Activators & Modulators

Product Name	JAK1	JAK2	JAK3	Tyk2	JAK	Purity
Ruxolitinib	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM		99.99%
Tofacitinib	JAK1, IC₅₀: 112 nM	JAK2, IC₅₀: 20 nM	JAK3, IC₅₀: 1 nM			99.99%
Deucravacitinib	JAK1 JH2, IC₅₀: 1 nM			Tyk2 JH2, IC₅₀: 0.2 nM		99.87%
Baricitinib	JAK1, IC₅₀: 5.9 nM	JAK2, IC₅₀: 5.7 nM	JAK3, IC₅₀: 560 nM	Tyk2, IC₅₀: 53 nM		99.97%
Upadacitinib	JAK1, IC₅₀: 0.043 μM	JAK2, IC₅₀: 0.2 μM	JAK3, IC₅₀: 2.3 μM	Tyk2, IC₅₀: 4.7 μM		99.98%
Oclacitinib	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 99 nM	Tyk2, IC₅₀: 84 nM		99.23%
Fedratinib		JAK2, IC₅₀: 3 nM JAK2(V617F), IC₅₀: 3 nM				99.87%
Ruxolitinib phosphate	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM		99.98%
Ritlecitinib			JAK3, IC₅₀: 33.1 nM			99.98%
Pacritinib	JAK1, IC₅₀: 1280 nM	JAK2^V617F, IC₅₀: 19 nM JAK2^wt, IC₅₀: 23 nM	JAK3, IC₅₀: 520 nM	Tyk2, IC₅₀: 50 nM		99.93%
Tofacitinib citrate	JAK1, IC₅₀: 112 nM	JAK2, IC₅₀: 20 nM	JAK3, IC₅₀: 1 nM			99.98%
WP1066		JAK2				99.77%
Momelotinib	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM			99.37%
Butyzamide		JAK2				99.62%
Filgotinib	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 28 nM	JAK3, IC₅₀: 810 nM	Tyk2, IC₅₀: 116 nM		99.68%
RO8191	JAK1					≥99.0%
AZD-1480	JAK1, IC₅₀: 1.3 nM	JAK2, IC₅₀: <0.4 nM				99.56%
AT9283		JAK2, IC₅₀: 1.2 nM	JAK3, IC₅₀: 1.1 nM			99.70%
Peficitinib	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM		99.43%
Abrocitinib	JAK1, IC₅₀: 29 nM	JAK2, IC₅₀: 803 nM		Tyk2, IC₅₀: 1253 nM		99.26%
CHZ868		JAK2, IC₅₀: 110 nM				99.56%
Itacitinib	JAK1					99.97%
Cucurbitacin I		JAK2				99.44%
(E/Z)-Zotiraciclib		JAK2, IC₅₀: 73 nM				99.96%
Gandotinib		JAK2, IC₅₀: 3 nM	JAK3, IC₅₀: 48 nM	Tyk2, IC₅₀: 44 nM		99.82%
Pyridone 6	Murine JAK1, IC₅₀: 15 nM	JAK2, IC₅₀: 1 nM	JAK3, IC₅₀: 5 nM	Tyk2, IC₅₀: 1 nM		98.13%
Baricitinib phosphate	JAK1, IC₅₀: 5.9 nM	JAK2, IC₅₀: 5.7 nM	JAK3, IC₅₀: 560 nM	Tyk2, IC₅₀: 53 nM		99.91%
Delgocitinib	JAK1, IC₅₀: 2.8 nM	JAK2, IC₅₀: 2.6 nM	JAK3, IC₅₀: 13 nM	Tyk2, IC₅₀: 58 nM		99.87%
Cerdulatinib	JAK1, IC₅₀: 12 nM	JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 8 nM	Tyk2, IC₅₀: 0.5 nM		98.96%
Ruxolitinib (S enantiomer)					JAK	99.77%
Fedratinib hydrochloride hydrate		JAK2, IC₅₀: 3 nM JAK2(V617F), IC₅₀: 3 nM				99.89%
Decernotinib	JAK1, Ki: 11 nM	JAK2, Ki: 13 nM	JAK3, Ki: 2.5 nM	Tyk2, Ki: 11 nM		99.67%
Oclacitinib maleate	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 99 nM	Tyk2, IC₅₀: 84 nM		99.63%
Lestaurtinib		JAK2, IC₅₀: 0.9 nM				99.17%
TG101209		JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 169 nM			99.22%
CEP-33779		JAK2, IC₅₀: 1.8 nM	JAK3, IC₅₀: 150 nM			99.23%
BMS-911543	JAK1, IC₅₀: 75 nM	JAK2, IC₅₀: 1.1 nM	JAK3, IC₅₀: 360 nM	Tyk2, IC₅₀: 66 nM		98.53%
AZ960		JAK2, Ki: 0.45 nM JAK2, IC₅₀: <3 nM	JAK3, IC₅₀: 9 nM
BMS-986202				Tyk2 JH2, IC₅₀: 0.19 nM Tyk2 JH2, Ki: 0.02 nM		99.92%
Golidocitinib	JAK1, IC₅₀: 73 nM					99.75%
Brepocitinib P-Tosylate	JAK1, IC₅₀: 17 nM	JAK2, IC₅₀: 77 nM	JAK3, IC₅₀: 6.9 μM			99.86%
XL019		JAK2, IC₅₀: 2.2 nM	JAK3, IC₅₀: 214.2 nM			≥98.0%
Ilginatinib	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		99.53%
NSC 42834		JAK2-WT, IC₅₀: 15 μM JAK2-V617F, IC₅₀: 28 μM				98.01%
RGB-286638		JAK2, IC₅₀: 50 nM				99.84%
JANEX-1			JAK3, IC₅₀: 78 μM			99.84%
VVD-118313	JAK1					99.75%
SAR-20347	JAK1, IC₅₀: 23 nM	JAK2, IC₅₀: 26 nM	JAK3, IC₅₀: 41 nM	Tyk2, IC₅₀: 0.6 nM
BD750			JAK3			99.10%
Broussonin E		JAK2				98.18%
Solcitinib	JAK1, IC₅₀: 9.8 nM					99.73%
WHI-P154			JAK3, IC₅₀: 1.8 μM			99.39%
Momelotinib sulfate	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM			98.06%
Tyk2-IN-5				Tyk2 JH2, Ki: 0.086 nM		98.87%
SJ10542		JAK2, DC₅₀: 14 nM	JAK3, DC₅₀: 11 nM			99.92%
JAK2-IN-6		JAK2, IC₅₀: 22.86 μg/mL				99.14%
Brepocitinib	JAK1, IC₅₀: 17 nM	JAK2, IC₅₀: 77 nM	JAK3, IC₅₀: 6.9 μM			98.64%
TyK2-IN-2				Tyk2 JH2, IC₅₀: 7 nM		98.64%
NVP-BSK805	JAK1 JH1, IC₅₀: 31.63 nM	JAK2 JH1, IC₅₀: 0.48 nM FL JAK2 V617F, IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM	JAK3 JH1, IC₅₀: 18.68 nM	TYK2 JH1, IC₅₀: 10.76 nM		99.89%
ZM39923 hydrochloride	JAK1, pIC₅₀: 4.4		JAK3, pIC₅₀: 7.1			98.19%
Itacnosertib		JAK2				99.77%
JAK3-IN-6			JAK3, IC₅₀: 0.15 nM			99.90%
Ivarmacitinib	JAK1	JAK2	JAK3	Tyk2		99.82%
NVP-BSK805 dihydrochloride	JAK1 JH1, IC₅₀: 31.63 nM	JAK2 JH1, IC₅₀: 0.48 nM FL JAK2 V617F, IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM	JAK3 JH1, IC₅₀: 18.68 nM	TYK2 JH1, IC₅₀: 10.76 nM		99.36%
Londamocitinib	JAK1, IC₅₀: 0.54 nM					98.98%
Cerdulatinib hydrochloride	JAK1, IC₅₀: 12 nM	JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 8 nM	Tyk2, IC₅₀: 0.5 nM		99.89%
Itacitinib adipate	JAK1					99.18%
Reticuline		JAK2				98.91%
JAK-IN-23	JAK1, IC₅₀: 8.9 nM	JAK2, IC₅₀: 15 nM	JAK3, IC₅₀: 46.2 nM			98.90%
JAK2/FLT3-IN-1	JAK1, IC₅₀: 26 nM	JAK2, IC₅₀: 0.7 nM	JAK3, IC₅₀: 39 nM			99.79%
Protosappanin A		JAK2				99.98%
TCS 21311	JAK1, IC₅₀: 1.017 μM	JAK2, IC₅₀: 2.55 μM	JAK3, IC₅₀: 8 nM			99.18%
Ilginatinib hydrochloride	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		≥98.0%
GSK2646264		JAK2, pIC₅₀: 5				98.39%
JAK2-IN-7	JAK1, IC₅₀: 42 nM	JAK2, IC₅₀: 3 nM	JAK3, IC₅₀: 94 nM	Tyk2, IC₅₀: 75 nM		99.15%
BI-1622			JAK3			98.97%
JAK2/FLT3-IN-1 TFA	JAK1, IC₅₀: 26 nM	JAK2, IC₅₀: 0.7 nM	JAK3, IC₅₀: 39 nM			99.77%
PF-06263276	JAK1, IC₅₀: 2.2 nM	JAK2, IC₅₀: 23.1 nM	JAK3, IC₅₀: 59.9 nM	Tyk2, IC₅₀: 29.7 nM		99.38%
FM-381			JAK3, IC₅₀: 127 pM			99.58%
SC99		JAK2				98.96%
WHI-P97			JAK3, IC₅₀: 11 μM			99.70%
Tyk2-IN-7				Tyk2 JH2, IC₅₀: 0.00053 μM Tyk2 JH2, Ki app: 0.00007 μM		99.62%
(E/Z)-Zotiraciclib citrate		JAK2				98.06%
SJ988497		JAK2				98.05%
JAK1-IN-8	JAK1, IC₅₀: <500 nM	JAK2, IC₅₀: 500-1000 nM	JAK3, IC₅₀: >5000 nM
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK1, Ki: 0.7 nM	JAK2, Ki: 0.7 nM	JAK3, Ki: 0.4 nM	Tyk2, Ki: 4.8 nM		98.78%
JAK2 JH2 binder-1		JAK2 JH2, Kd: 37.1 nM
(E/Z)-Zotiraciclib hydrochloride		JAK2				99.45%
Deuruxolitinib	JAK1	JAK2				99.18%
JAK3-IN-1	JAK1, IC₅₀: 896 nM	JAK2, IC₅₀: 1050 nM	JAK3, IC₅₀: 4.8 nM			99.23%
(2R,5S)-Ritlecitinib			JAK3, IC₅₀: 144.8 nM			98.83%
G5-7		JAK2				99.55%
SJ1008030 TFA		JAK2				99.81%
RGB-286638 free base		JAK2, IC₅₀: 50 nM				98.07%
GLPG0634 analog	JAK1, IC₅₀: <100 nM	JAK2, IC₅₀: <100 nM	JAK3, IC₅₀: <100 nM	Tyk2, IC₅₀: <100 nM		98.58%
Ilginatinib maleate	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		99.87%
(R,R)-VVD-118313	JAK1					99.54%
SD-1029		JAK2
JAK-IN-3	JAK1, IC₅₀: 5 nM	JAK2, IC₅₀: 70 nM	JAK3, IC₅₀: 3 nM	Tyk2, IC₅₀: 34 nM		98.92%
JAK1-IN-4	JAK1, IC₅₀: 85 nM	JAK2, IC₅₀: 12.8 μM
GS-829845	JAK1					99.91%
SJ1008030 formic		JAK2
JAK-IN-11					JAK	98.62%
JAK-IN-10					JAK
Peficitinib hydrobromide	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM
Upadacitinib tartrate tetrahydrate	JAK1, IC₅₀: 0.043 μM	JAK2, IC₅₀: 0.2 μM	JAK3, IC₅₀: 2.3 μM	Tyk2, IC₅₀: 4.7 μM
JAK3 covalent inhibitor-1			JAK3, IC₅₀: 11 nM
NVP-BSK805 trihydrochloride	JAK1 JH1, IC₅₀: 31.68 nM	JAK2 JH1, IC₅₀: 0.48 nM JAK2(V617F), IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM		TYK2 JH1, IC₅₀: 18.68 nM
Nezulcitinib					JAK
Filgotinib maleate	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 28 nM	JAK3, IC₅₀: 810 nM	Tyk2, IC₅₀: 116 nM
ABBV-712	JAK1, IC₅₀: 80 μM
Pacritinib hydrochloride	JAK1, IC₅₀: 1280 nM	JAK2^V617F, IC₅₀: 19 nM JAK2^wt, IC₅₀: 23 nM	JAK3, IC₅₀: 520 nM	Tyk2, IC₅₀: 50 nM
TUL01101	JAK1, IC₅₀: 3 nM	JAK2, IC₅₀: 37 nM	JAK3, IC₅₀: 1517 nM	Tyk2, IC₅₀: 36 nM
JAK-2/3-IN-1		JAK2, Ki: <250 nM	JAK3, Ki: <250 nM
Peficitinib hydrochloride	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM
JAK-IN-21	JAK1, IC₅₀: 1.73 nM	JAK2, IC₅₀: 2.04 nM JAK2-V617F, IC₅₀: 109 nM		Tyk2, IC₅₀: 62.9 nM		99.72%
DPPY			JAK3, IC₅₀: <10 nM
NSC 33994		JAK2, IC₅₀: 60 nM (JAK2 Val617Phe kinase activity )
JAK3-IN-12	JAK1, IC₅₀: 18 nM	JAK2, IC₅₀: 42 nM	JAK3, IC₅₀: 9.5 nM
JAK3 covalent inhibitor-2			JAK3, IC₅₀: 7.2 nM
JAK2/TYK2-IN-1		JAK2, IC₅₀: 157 nM		Tyk2, IC₅₀: 9 nM
Thi-DPPY			JAK3, IC₅₀: 1.38 nM
JAK1/2-IN-1	JAK1, IC₅₀: 0.4 nM	JAK2, IC₅₀: 8.1 nM
ZT55		JAK2, IC₅₀: 0.031 μM
JAK1-IN-14	JAK1, IC₅₀: 12.6 nM	JAK2, IC₅₀: 135 nM
MS-1020			JAK3
Ten01	JAK1, IC₅₀: 5 nM
JI6			JAK3, IC₅₀: ~250 nM
JAK/HDAC-IN-2	JAK1, IC₅₀: 27.15 nM	JAK2, IC₅₀: 5.32 nM	JAK3, IC₅₀: 594.8 nM	Tyk2, IC₅₀: 414.4 nM
JAK-IN-30	JAK1, IC₅₀: 15 nM	JAK2, IC₅₀: 2 nM	JAK3, IC₅₀: 18 nM	Tyk2, IC₅₀: 2 nM
JAK3-IN-11	JAK1, IC₅₀: 1.32 μM	JAK2, IC₅₀: 1 μM	JAK3, IC₅₀: 1.7 nM
JAK 3i	JAK1, IC₅₀: 1520 nM	JAK2, IC₅₀: 8680 nM	JAK3, IC₅₀: 0.43 nM
MTP		JAK2
JAK2-IN-9		JAK2
JAK1-IN-12	JAK1, IC₅₀: 0.0246 μM	JAK2, IC₅₀: 0.423 μM	JAK3, IC₅₀: 0.410 μM	Tyk2, IC₅₀: 1.12 μM
LRRK2-IN-8				Tyk2, IC₅₀: 10-100 nM
JAK-IN-36	JAK1, IC₅₀: 2.2 nM
HG-7-85-01	JAK1, IC₅₀: 120 nM					99.94%
PF-00956980	JAK1, IC₅₀: 2.2 μM	JAK2, IC₅₀: 23.1 μM	JAK3, IC₅₀: 59.9 μM
JAK1-IN-10	JAK1
TYK2-IN-12	JAK1, Ki: 45.9 nM	JAK2, Ki: 21.93 nM	JAK3, Ki: 6.63 nM	Tyk2, Ki: 0.51 nM
JAK-IN-25	JAK1, IC₅₀: 21 nM	JAK2, IC₅₀: 8 nM	JAK3, IC₅₀: 1051 nM	Tyk2, IC₅₀: 6 nM		98.44%
JAK-2/3-IN-2		JAK2, IC₅₀: 23.85 nM	JAK3, IC₅₀: 18.9 nM
FM-479			JAK3
JAK-2/3-IN-3		JAK2, IC₅₀: 13.00 nM	JAK3, IC₅₀: 14.86 nM
JAK1/TYK2-IN-3	JAK1, IC₅₀: 37 nM	JAK2, IC₅₀: 140 nM	JAK3, IC₅₀: 362 nM	Tyk2, IC₅₀: 6 nM
JAK3-IN-9			JAK3, IC₅₀: 1.7 nM
TCJL37				Tyk2, Ki: 1.6 nM
LRRK2/NUAK1/TYK2-IN-1				Tyk2
TK4g		JAK2, IC₅₀: 12.61 nM	JAK3, IC₅₀: 15.80 nM
JAK3-IN-14		JAK2, IC₅₀: 600 nM	JAK3, IC₅₀: 38 nM			99.32%
JAK3/BTK-IN-6	JAK1, IC₅₀: >1000 nM	JAK2, IC₅₀: 657.9 nM	JAK3, IC₅₀: 0.4 nM	Tyk2, IC₅₀: >1000 nM
Tyk2-IN-16				Tyk2 JH2, IC₅₀: <10 nM
TK4b		JAK2, IC₅₀: 19.40 nM	JAK3, IC₅₀: 18.42 nM
JAK-IN-34	JAK1, IC₅₀: 0.40 nM	JAK2, IC₅₀: 0.83 nM	JAK3, IC₅₀: 2.10 nM	Tyk2, IC₅₀: 1.95 nM
JAK1-IN-9	JAK1, IC₅₀: 72 nM	JAK2, IC₅₀: 839 nM
JAK-IN-20	JAK1, IC₅₀: 7 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 14 nM
Ruxolitinib sulfate	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM
Momelotinib Mesylate	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM
AT9283 lactic acid		JAK2, : 1.2 nM	JAK3, : 1.1 nM
SD-1008		JAK2
ZM39923	JAK1, pIC₅₀: 4.4		JAK3, pIC₅₀: 7.1
JAK-IN-4					JAK
BMS-066				Tyk2, IC₅₀: 72 nM
Tyk2-IN-3				Tyk2, IC₅₀: 485 nM
JAK3-IN-7			JAK3, IC₅₀: 0.01 μM

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)	站点地图隐私声明
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.	沪ICP备15051369号-4

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)

站点地图隐私声明

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

JAK Inhibitors

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z